1. Home
  2. RDHL vs CINGW Comparison

RDHL vs CINGW Comparison

Compare RDHL & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • CINGW
  • Stock Information
  • Founded
  • RDHL 2009
  • CINGW N/A
  • Country
  • RDHL Israel
  • CINGW United States
  • Employees
  • RDHL N/A
  • CINGW 13
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • RDHL Health Care
  • CINGW Health Care
  • Exchange
  • RDHL Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • RDHL N/A
  • CINGW N/A
  • IPO Year
  • RDHL N/A
  • CINGW 2021
  • Fundamental
  • Price
  • RDHL $2.24
  • CINGW $0.04
  • Analyst Decision
  • RDHL
  • CINGW
  • Analyst Count
  • RDHL 0
  • CINGW 0
  • Target Price
  • RDHL N/A
  • CINGW N/A
  • AVG Volume (30 Days)
  • RDHL 430.2K
  • CINGW N/A
  • Earning Date
  • RDHL 04-10-2025
  • CINGW N/A
  • Dividend Yield
  • RDHL N/A
  • CINGW N/A
  • EPS Growth
  • RDHL N/A
  • CINGW N/A
  • EPS
  • RDHL N/A
  • CINGW N/A
  • Revenue
  • RDHL $8,042,999.00
  • CINGW N/A
  • Revenue This Year
  • RDHL $381.91
  • CINGW N/A
  • Revenue Next Year
  • RDHL N/A
  • CINGW N/A
  • P/E Ratio
  • RDHL N/A
  • CINGW N/A
  • Revenue Growth
  • RDHL 23.17
  • CINGW N/A
  • 52 Week Low
  • RDHL $1.80
  • CINGW N/A
  • 52 Week High
  • RDHL $20.28
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 40.62
  • CINGW N/A
  • Support Level
  • RDHL $1.72
  • CINGW N/A
  • Resistance Level
  • RDHL $2.49
  • CINGW N/A
  • Average True Range (ATR)
  • RDHL 0.34
  • CINGW 0.00
  • MACD
  • RDHL 0.05
  • CINGW 0.00
  • Stochastic Oscillator
  • RDHL 32.91
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: